search
Back to results

Examining the Effect of the Nicotine Patch in Male and Female Smokers - 3

Primary Purpose

Drug Addiction, Smoking Cessation

Status
Completed
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
nicotine transdermal system
Nicotine transdermal system
Nicotine containing cigarette
Placebo cigarette
Sponsored by
Virginia Commonwealth University
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional basic science trial for Drug Addiction focused on measuring Nicotine Replacement Therapy, Tobacco Smoking, Smoking stimuli, Gender

Eligibility Criteria

18 Years - 50 Years (Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria include, but are not limited to:

18-50 years of age Smokes 15 cigarettes/day for at least 2 years Healthy (as determined by a brief study physical with medical doctor) Displays understanding of cognitive tasks.

Exclusion Criteria include, but are not limited to:

History of chronic health problems or psychiatric conditions History of cardiovascular disease, low or high blood pressure, seizures, head injuries requiring hospital care, peptic ulcer, or diabetes Pregnancy (tested by urinalysis) Scores greater than 17 on the Beck Depression Inventory Lack of a high school degree or GED

Sites / Locations

  • Virginia Commonwealth University - Clinical Behavioral Pharmacology Laboratory

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm Type

Experimental

Experimental

Experimental

Experimental

Arm Label

ActiveP/ActiveC

PlaceboP/ActiveC

Active P/PlaceboC

PlaceboP/PlaceboC

Arm Description

21 mg patch/Nicotine-containing cigarette

0 mg patch/nicotine-containing cigarette

21 mg patch/no nicotine cigarette

0 mg patch/no nicotine cigarette

Outcomes

Primary Outcome Measures

Subjective Effects
The full scale name is the "Urge to smoke" visual analog scale (VAS). It measures self-reported "urge to smoke". As with any VAS a word or phrase (in this case, "Urge to Smoke" is centered over a horizontal line anchored on the left by "not at all" and on the right by "extremely." In this study, participants used a mouse to produce a vertical mark on the horizontal line, and the score was the distance of the mark from the left anchor expressed as a percentage of total line length. Thus, the minimum was 0 ("not at all") and the maximum score was 100 ("extremely").

Secondary Outcome Measures

Full Information

First Posted
October 18, 2006
Last Updated
July 6, 2012
Sponsor
Virginia Commonwealth University
Collaborators
National Institute on Drug Abuse (NIDA)
search

1. Study Identification

Unique Protocol Identification Number
NCT00390559
Brief Title
Examining the Effect of the Nicotine Patch in Male and Female Smokers - 3
Official Title
Effects of Transdermal Nicotine on Tobacco Withdrawal and the Effects of Smoking-related Stimuli in Men and Women
Study Type
Interventional

2. Study Status

Record Verification Date
July 2012
Overall Recruitment Status
Completed
Study Start Date
October 2005 (undefined)
Primary Completion Date
March 2008 (Actual)
Study Completion Date
March 2008 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Virginia Commonwealth University
Collaborators
National Institute on Drug Abuse (NIDA)

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
Treatment studies have demonstrated that current smoking cessation techniques are less effective for women. The purpose of this study is to determine the role that gender plays in the effectiveness of nicotine replacement therapy. In addition, the purpose of this study is to determine whether men and women differ in their response to smoking-related stimuli (e.g., taste or smell of a lit cigarette). Conclusions drawn from this study may help to improve cessation interventions for all smokers, particularly women.
Detailed Description
Currently,about 70 percent of smokers who try to quit by using smoking cessation treatments are unsuccessful. Treatment studies have demonstrated that current smoking cessation techniques are less effective for women. There is no clear explanation for this difference, but it may involve a differential response to nicotine replacement treatments (NRTs) and/or smoking-related stimuli. For women, NRT may be less effective at suppressing withdrawal or blunting the effects of smoking during a quit attempt. Women may also be more sensitive to smoking-related stimuli, suc has the taste, sight, or smell of cigarette smoke. Tailoring treatments to the separate needs of smoker subgroups , such as men and women, my produce better cessation outcomes. The purpose of this study is to assess whether men and women differ in the their response to NRT (i.e., transdermal nicotine) and smoking-related stimuli. Participants in this double-blind, dose-comparison study will complete separate sessions in random order. Each session will last approximately 6.5 hours and will correspond to a transdermal patch dose (0 or 21mg) and cigarette type (denicotinized and nicotinized). Objectively verified cigarette abstinence will be required before each session. Sessions will occur at least 48 hours apart to avoid carryover. At the beginning of each session a patch will be placed on the participant's back and at 4, 5, and 6 hours after patch application the participant will smoke a cigarette (all identifying marking on the cigarette will be covered for blinding purposes). Physiological, subjective, cognitive, and smoking behavior outcomes will be collected during study visits.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Drug Addiction, Smoking Cessation
Keywords
Nicotine Replacement Therapy, Tobacco Smoking, Smoking stimuli, Gender

7. Study Design

Primary Purpose
Basic Science
Study Phase
Not Applicable
Interventional Study Model
Crossover Assignment
Masking
ParticipantOutcomes Assessor
Allocation
Non-Randomized
Enrollment
80 (Actual)

8. Arms, Groups, and Interventions

Arm Title
ActiveP/ActiveC
Arm Type
Experimental
Arm Description
21 mg patch/Nicotine-containing cigarette
Arm Title
PlaceboP/ActiveC
Arm Type
Experimental
Arm Description
0 mg patch/nicotine-containing cigarette
Arm Title
Active P/PlaceboC
Arm Type
Experimental
Arm Description
21 mg patch/no nicotine cigarette
Arm Title
PlaceboP/PlaceboC
Arm Type
Experimental
Arm Description
0 mg patch/no nicotine cigarette
Intervention Type
Drug
Intervention Name(s)
nicotine transdermal system
Other Intervention Name(s)
Nicoderm CQ
Intervention Description
21 mg nicotine transdermal system
Intervention Type
Drug
Intervention Name(s)
Nicotine transdermal system
Intervention Description
Placebo nicotine patch
Intervention Type
Other
Intervention Name(s)
Nicotine containing cigarette
Intervention Description
Nicotine containing cigarette
Intervention Type
Other
Intervention Name(s)
Placebo cigarette
Intervention Description
Non nicotine containing cigarette
Primary Outcome Measure Information:
Title
Subjective Effects
Description
The full scale name is the "Urge to smoke" visual analog scale (VAS). It measures self-reported "urge to smoke". As with any VAS a word or phrase (in this case, "Urge to Smoke" is centered over a horizontal line anchored on the left by "not at all" and on the right by "extremely." In this study, participants used a mouse to produce a vertical mark on the horizontal line, and the score was the distance of the mark from the left anchor expressed as a percentage of total line length. Thus, the minimum was 0 ("not at all") and the maximum score was 100 ("extremely").
Time Frame
6 hours

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
50 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria include, but are not limited to: 18-50 years of age Smokes 15 cigarettes/day for at least 2 years Healthy (as determined by a brief study physical with medical doctor) Displays understanding of cognitive tasks. Exclusion Criteria include, but are not limited to: History of chronic health problems or psychiatric conditions History of cardiovascular disease, low or high blood pressure, seizures, head injuries requiring hospital care, peptic ulcer, or diabetes Pregnancy (tested by urinalysis) Scores greater than 17 on the Beck Depression Inventory Lack of a high school degree or GED
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Thomas E Eissenberg, PhD
Organizational Affiliation
Virginia Commonwealth University Department of Psychology, Institute for Drug and Alcohol Studies
Official's Role
Principal Investigator
Facility Information:
Facility Name
Virginia Commonwealth University - Clinical Behavioral Pharmacology Laboratory
City
Richmond
State/Province
Virginia
ZIP/Postal Code
23298
Country
United States

12. IPD Sharing Statement

Learn more about this trial

Examining the Effect of the Nicotine Patch in Male and Female Smokers - 3

We'll reach out to this number within 24 hrs